Today we are talking to Tom Barnes. Tom is CEO of Orna Therapeutics, a circular RNA focused biotech developing in situ CAR therapeutics. Orna recently announced a series B with a multi billion $ mega-deal with Merck. Prior to Orna Tom and I worked together at Intellia and also Ascelagen. Tom has also had leading positions at Eleven Bio and Millennium. Tom has deep biological pathway domain expertise and has worked across a broad range of therapeutic modalities, from genome editing, to RNA therapeutics, small molecules and proteins. Tom is a true scientist and drug hunter.
Today we are talking to Tom Barnes. Tom is CEO of Orna Therapeutics, a circular RNA focused biotech developing in situ CAR therapeutics. Orna recently announced a series B with a multi billion $ mega-deal with Merck. Prior to Orna Tom and I worked together at Intellia and also Ascelagen. Tom has also had leading positions at Eleven Bio and Millennium. Tom has deep biological pathway domain expertise and has worked across a broad range of therapeutic modalities, from genome editing, to RNA therapeutics, small molecules and proteins. Tom is a true scientist and drug hunter.